FL-EXACTECH
16.9.2021 16:08:13 CEST | Business Wire | Press release
Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today that the first anatomic total shoulder surgery has been performed in Europe using its bone-conserving, 3D-printed Equinoxe® Stemless Shoulder. Prof. Mark Tauber, MD, PhD, of Athos Klinik in Munich, Germany, performed the first surgery earlier this month.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210916005561/en/
“It was wonderful to be the first user of the Exactech Stemless humeral component in Europe,” Tauber said. “I’ve used stemless implants with various systems since 2007, so I know what we are talking about and have to congratulate Exactech for this product. The user-friendly instrumentation and implant design features made a really convincing impression regarding primary stability.”
The Equinoxe Stemless Shoulder was introduced in the U.S. in 2018 and is manufactured using direct metal 3D printing with high precision lasers to create its porous bone cage. This humeral component’s bone cage structure is designed for initial press-fit and biologic fixation.
“We are thrilled to offer this innovative product to our European partners, surgeons and patients. We hope this implant helps many patients get back to what they love, and we look forward to supporting our sales team members and surgeon customers,” said Bruce Thompson, Exactech’s Senior Vice President of International Sales.
Additional features of the product include the humeral component's optimized pore size, count and porosity, as well as surgical efficiency through its single instrument tray. Surgeons can also use it in conjunction with the Equinoxe Shoulder System's standard and augmented glenoid solutions.
The Stemless Shoulder was designed with doctors Curtis Noel, of the Crystal Clinic in Akron, Ohio; Felix “Buddy” Savoie, of Tulane University in New Orleans, La.; Pierre-Henri Flurin, of Clinique du Sport in Bordeaux-Mérignac, France; Ryan Simovitch, of HSS Florida in West Palm Beach, Fla.; Thomas Wright, of the University of Florida, in Gainesville, Fla.; and Joseph Zuckerman, of NYU Langone Orthopaedic Hospital, in New York City.
Exactech plans to roll out additional inventory throughout the rest of 2021. Interested surgeons can learn more about the implant and its instrumentation at upcoming society shows throughout Europe or by visiting each country’s website:
- Germany - https://de.exac.com/schulter/equinoxe-stemless-shoulder/
- Spain - https://www.exac.es/hombro/equinoxe-stemless-shoulder/
- United Kingdom - https://www.exac.co.uk/shoulder/equinoxe-stemless-shoulder/
- France - https://www.exactech.fr/epaule/equinoxe-stemless-shoulder/
About Exactech
Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn , VuMedi , YouTube , Instagram and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005561/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
